Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment

Launch Of Humira Challenger In 2023 May Rejuvenate The Area

 
• By Chloe Kent

Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.

Pfizer logo next to syringe
Pfizer's biosimilar business appears to be on the backburner for the time being • Source: Shutterstock

More from Biosimilars

More from Products